Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO examines food import safety gaps

This article was originally published in The Tan Sheet

Executive Summary

A lack of coordination between the agencies that oversee imported food could allow high-risk foods to enter domestic commerce, says a Government Accountability Office 1report released Oct. 14. Gaps arise in part because FDA, the Department of Agriculture's Food Safety Inspection Service and the Department of Homeland Security's Customs and Border Protection division do not have fully interoperable computer systems, GAO says. Additionally, FDA has limited authority to ensure importer compliance and does not assign unique identification numbers to manufacturers, making it difficult to target past violators, the report notes. FDA's response to the report points out the pending Food Safety Enhancement Act, H.R. 2749, would authorize the agency to institute a system of unique numerical identifiers for food firms (2"The Tan Sheet" Sept. 21, 2009)

You may also be interested in...

FDA Stresses Preventive Food Safety As Senate Readies To Move Legislation

FDA is preparing to extend preventive approaches to all food safety areas as the Senate elevates the priority of related legislation

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts